Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.

Inclusion Criteria: An IRB/IEC approved written informed consent form signed and dated Male/Female patients age 18 (or 16 years where permitted by law) to 65. Minimum body weight of 40 kg. Patients with a confirmed diagnosis of refractory epilepsy of ≥ 6 months. Patients must be receiving 1 - 3 concomitant AEDs. Female patients without childbearing potentials (2 years post-menopausal or surgical sterilization) are eligible. Female patients with childbearing potential are eligible if they use a medically accepted non-hormonal contraceptive method. Exclusion Criteria: Seizures occurring in clusters (seizures occurring either too frequently or indistinctly separated to be reliably counted). Status epilepticus within 3 months of Visit 1. History of non-epileptic seizures. Patients on vigabatrin. Patients on felbamate, unless treatment has been continuous for ≥ 18 months. Use of benzodiazepines (for any indication) taken at a higher frequency than an average of once a week, unless counted as one of the concomitant AEDs. Ongoing psychiatric disease other than mild controlled disorders. Patients with a clinically significant organ dysfunction. Known allergic reaction or intolerance to pyrrolidine derivatives and/or excipients. Pregnant or lactating women. Any woman with childbearing potential who is not using a medically accepted, non-hormonal method of birth control.